Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...
GlobalData on MSN
Moderna’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...
The researchers note that circadian rhythms - the 24-hour cycles governing biological processes - are known to influence ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results